Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2013-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prolonged Collagen/Epinephrine - closure time (CEPI-CT) indicates platelet dysfunction in CKD patients taking antiplatelet agent. The synthetic vasopressin derivative, Desmopressin (DDAVP) shortens the prolonged bleeding time and improves platelet dysfunction measured by in vitro closure time: CEPI-CT in uremic patients. Desmopressin also antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors, clopidogrel and aspirin. The investigators designed a prospective study to evaluate the effect of desmopressin on platelet function, as measured by in vitro collagen/epinephrine - closure time, in uremic patients who were taking antiplatelet drugs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin

NCT05467033

Kidney Biopsy

RECRUITING PHASE3

Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis

NCT01241539

Cardiovascular Diseases Kidney Failure, Chronic

COMPLETED PHASE1

Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia

NCT00374712

Chronic Kidney Disease End Stage Renal Disease Hyperphosphatemia +1 more

TERMINATED

Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis

NCT03289520

Kidney Failure Hemodialysis Fistula Thrombosis

COMPLETED PHASE3

A Study of Ferric Citrate to Improve Inflammation and Lipid Levels

NCT02661295

End Stage Renal Disease Hyperphosphatemia Chronic Inflammation

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bleeding Tachycardia Dyspnea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Desmopressin

Twenty five patients with chronic kidney disease and who were taking antiplatelet agents and needed an emergent catheter insertion for hemodialysis

Group Type EXPERIMENTAL

Desmopressin administration

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Desmopressin administration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adult uremic patients with one or more antiplatelet medication,
* prolonged collagen/epinephrine (CEPI) closure time,
* need for emergent hemodialysis and
* subsequent catheter insertion